Mirabegron for Overactive Bladder Treatment

Clinical Efficacy and Safety

Mirabegron is an effective second-line pharmacologic treatment for overactive bladder with urge urinary incontinence, offering comparable efficacy to antimuscarinics but with significantly lower rates of dry mouth and other anticholinergic side effects, as supported by the American Urological Association 1
For patients inadequately responding to mirabegron monotherapy, combination with an antimuscarinic agent (specifically solifenacin 5 mg) is supported by Grade B evidence from the European Association of Urology 1, 2
Mirabegron 50 mg + solifenacin 5 mg demonstrates statistically superior efficacy compared to either monotherapy for reducing incontinence episodes, urgency episodes, and nocturia, according to the International Continence Society 1, 2, 3
Combination therapy shows slightly increased rates of dry mouth, constipation, and dyspepsia compared to monotherapy, with more frequent urinary retention events, as reported by the American Urological Association 1, 2

Renal impairment dosing: for patients with eGFR 30-89 mL/min/1.73 m², start 25 mg, max 50 mg daily, as recommended by the National Kidney Foundation 3
Hepatic impairment dosing: for patients with Child-Pugh Class A (mild), start 25 mg, max 50 mg daily, according to the American Association for the Study of Liver Diseases 4
Older patients (≥65 years): mirabegron 25 mg is particularly effective and safe in this population with multiple comorbidities, as stated by the American Geriatrics Society 4, 5

Periodically monitor blood pressure, especially in hypertensive patients and during initial treatment, as mirabegron can cause dose-dependent blood pressure increases, as advised by the American Heart Association 5
Common adverse events (>2%): hypertension, urinary tract infection, and headache, as reported by the Centers for Disease Control and Prevention 4, 2
Serious but rare adverse effects: angioedema of face, lips, tongue, and/or larynx, cardiac arrhythmias, kidney stones, and serious skin reactions, as warned by the Food and Drug Administration 2, 4

The American Urological Association recommends combination therapy with solifenacin 5 mg and mirabegron 25-50 mg once daily for patients with overactive bladder who remain symptomatic on monotherapy, as this combination provides superior efficacy compared to either drug alone with an acceptable safety profile 6

The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction guidelines recommend combination therapy specifically for patients who are refractory to monotherapy with either antimuscarinics or β3-adrenoceptor agonists, with Grade B evidence 6
Patients with persistent "wet" OAB symptoms, such as urinary frequency and urgency with incontinence, despite adequate trial of monotherapy, may benefit from combination therapy 6
Patients willing to engage in treatment and for whom further treatment is in their best interests may be considered for combination therapy 6

The American Urological Association recommends not using combination therapy as first-line treatment, but rather specifically for patients refractory to monotherapy 6
It is recommended to not skip the monotherapy trial, as guidelines emphasize combination therapy only after inadequate response to single agents 6
Co-administration of solifenacin and mirabegron has no noticeable effects on the pharmacokinetics of either drug, allowing safe concurrent use without dose adjustments based on drug interactions 6